Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
| Autor: | McGowan, Barbara M *, Bruun, Jens M, Capehorn, Matt, Pedersen, Sue D, Pietiläinen, Kirsi H, Muniraju, Hanna Angelene Kudiyanur, Quiroga, Maria, Varbo, Anette, Lau, David C W |
|---|---|
| Zdroj: | In The Lancet Diabetes & Endocrinology September 2024 12(9):631-642 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|